© 2005 Oxford University Press
NEWS |
Scientists Hopeful as They Uncover Molecular Clues to Prostate Cancer
| The first 150 words of the full text of this article appear below. |
The prostate-specific antigen (PSA) test took a beating this fall, with several long-term studies revealing it is not a stellar prognostic indicator. However, new findings on the genetic and molecular workings of prostate cancer are giving researchers new hope for better diagnostics and treatments for prostate cancer.
The original champion of the PSA test, Stanford University urologist Thomas A. Stamey, M.D., lost faith in PSA as a marker for prostate cancer after analyzing data from 1,300 radical prostatectomies performed over the last 20 years. He says that, today, PSA reflects only prostate enlargement. "There is an urgent need for serum markers that reflect the size and grade of this ubiquitous cancer," Stamey and colleagues wrote in October 2004 in the Journal of Urology.
A relatively low PSA level is also not a guarantee that cancer does not exist. In the Prostate Cancer Prevention Trial, 15% of men with PSA
Measuring Hedgehog
Tumor Suppressor Loss
Tumor Escape Mechanisms